Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy
Year: 2008
Type: article
Abstract: To identify factors associated with relapse-free survival (RFS), 80 patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia, enrolled in a phase II study of imatinib-combined chemotherapy, were analyzed. The median follow-up of surviving patients was 26.7 months (maximum, 52.5 months). Twenty-eight out of 77 patients who had achieved CR relapsed. The probability of RFS was 50.5% at 2 years. Multivariate analysis revealed that the presence of secondary chromosome aberrations in addition to t(9;22) at diagnosis constitute an independent predictive value for RFS (p=0.027), and increase the risk of treatment failure by 2.8-fold.
Source: Haematologica
Authors: M. Yanada, J. Takeuchi, I. Sugiura, H. Akiyama, N. Usui, F. Yagasaki, K. Nishii, Y. Ueda, M. Takeuchi, S. Miyawaki, A. Maruta, H. Narimatsu, Y. Miyazaki, S. Ohtake, I. Jinnai, K. Matsuo, T. Naoe, R. Ohno, for the Japan Adult Leukemia Study Group
Institutions: Nagoya University, Nihon University, Toyohashi Municipal Hospital, Tokyo Metropolitan Komagome Hospital, Jikei University School of Medicine, Saitama Medical University, Mie University, Kurashiki Central Hospital, National Hospital Organization Minami-Okayama Medical Center, Gunma Saiseikai Maebashi Hospital, Kanagawa Cancer Center, Nagasaki University, Kanazawa University, Aichi Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,157
OpenAlex ID: W2162801973